secwatch.observer — SEC 8-K summary
======================================

Issuer:     GT Biopharma, Inc. (GTBP)
CIK:        0000109657
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001493152-24-036381
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

GT Biopharma repositions Dr. Miller as Consulting Senior Medical Director for conflict-of-interest compliance
--------------------------------------------------------------------------------

- Dr. Jeffrey Miller ceased as Consulting Chief Medical Officer and Consulting Chief Scientific Officer effective September 16, 2024.
- He commenced as Consulting Senior Medical Director to align with University of Minnesota conflict-of-interest policies.
- The change precedes the Phase I clinical trial of GTB-3650 compound at the University of Minnesota.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/109657/000149315224036381/0001493152-24-036381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/109657/000149315224036381/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-036381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer